Table 2.
Invasive hemodynamics at week 6 after induction of aorto-caval fistula and after 2 weeks of treatment with soluble epoxide hydrolase inhibitor.
| Group | ||||||||
|---|---|---|---|---|---|---|---|---|
| Parameter | FHL | FHL | ACF FHL | ACF FHL | FHH | FHH | ACF FHH | ACF FHH |
| + | + | + | + | + | + | + | + | |
| water | sEHi | water | sEHi | water | sEHi | water | sEHi | |
| Heart rate (s-1) | 435 ± 19 | 432 ± 21 | 419 ± 27 | 4271 ± 22 | 416 ± 29 | 418 ± 31 | 405 ± 29 | 409 ± 27 |
| LV peak pressure (mmHg) | 137 ± 4 | 139 ± 4 | 112 ± 4* | 114 ± 4* | 149 ± 4# | 150 ± 3# | 126 ± 3*# | 127 ± 3*# |
| LV end-diastolic pressure (mmHg) | 1.9 ± 0.5 | 1.9 ± 0.4 | 8.6 ± 0.8* | 8.9 ± 0.7* | 1.7 ± 0.6 | 1.8 ± 0.4 | 8.7 ± 0.7* | 9.0 ± 0.9* |
| LV end-diastolic volume (ml) | 0.29 ± 0.09 | 0.30 ± 0.08 | 0.99 ± 0.06* | 1.04 ± 0.10* | 0.31 ± 0.06 | 0.32 ± 0.09 | 1.08 ± 0.11* | 1.06 ± 0.09* |
| +(dP/dt)max (mmHg.s-1) | 10972 ± 986 | 10732 ± 896 | 10742 ± 886 | 10963 ± 971 | 11563 ± 1001 | 11042 ± 952 | 11036 ± 896 | 11152 ± 992 |
| -(dP/dt)max (mmHg.s-1) | -9156 ± 832 | -9063 ± 776 | -9192 ± 874 | -9098 ± 836 | -9272 ± 914 | -9154 ± 857 | -9087 ± 798 | -9108 ± 783 |
| ESPVRmax (mmHg.ml-1) | 286 ± 39 | 256 ± 33 | 57 ± 17* | 61 ± 13* | 261 ± 37 | 256 ± 36 | 54 ± 13* | 58 ± 15* |
| EDPVRmax (mmHg.ml-1) | 43 ± 9 | 39 ± 7 | 14 ± 4* | 15 ± 4* | 42 ± 6 | 40 ± 6 | 13 ± 4* | 15 ± 4* |
| LV relaxation constant, tau (ms) | 13 ± 2 | 14 ± 3 | 27 ± 4* | 28 ± 3* | 11 ± 3 | 12 ± 3 | 28 ± 3* | 29 ± 3* |
Values are means ± SEM. LV, left ventricle; +(dP/dt)max, maximum rates of pressure rise; -(dP/dt)min, maximum rates of pressure fall; ESPVRmax, maximum end-systolic pressure-volume relationship; EDPVRmax, maximum end-diastolic pressure-volume relationship; FHL, fawn-hooded low-pressure rats; FHH, fawn-hooded hypertensive rats; ACF, aorto-caval fistula; sEHi, soluble epoxide hydrolase inhibitor. ∗P < 0.05 compared with sham-operated counterparts. #P < 0.05 FHH vs. FHL.